期刊文献+

高血压脑梗死患者血压变异性与血浆内皮素的关系探讨 被引量:5

Relationship between Blood Pressure Variability and Plasma Endothelin in Hypertensive Cerebral Infarction
下载PDF
导出
摘要 目的探讨高血压脑梗死患者的血压变异性与血浆内皮素的关系。方法对89例高血压脑梗死患者及39例高血压患者行24h动态血压监测,采静脉血用放射免疫法测定血浆内皮素。结果两组病例的24h平均收缩压、24h平均舒张压、脉压指数(脉压占收缩压比率)相仿,24h收缩压变异性、白昼收缩压变异性、内皮素含量高血压脑梗死组大于高血压组(P值分别为<0.01,<0.05和<0.01),而夜间收缩压变异性及所有舒张压变异性两组间无显著差异。结论血浆内皮素参与EH发生、发展,并加重脑血管的损害。 Objective To study the relationship between blood pressure variability and plasma endothelin in hypertensive cerebral infarction. Methods The 24h blood pressure monitoring was carried out in 89 cases of hypertensive cerebral infarction and 39 cases of essential hypertension,and plasma endothelin was measured with venous blood by radioimmunoassay. Results The two groups showed no significant difference in 24h mean systolic blood pressure, 24h mean diastolic blood pressure and pulse pressure index, and 24h systolic blood pressure variability, daytime systolic blood pressure variabihty and endothelin level in the hypertensive cerebral infarction group were higher than those of the essential hypertension group(P〈0.01 ,P〈0.05 and P〈0.01 ). Conclusion Plasma endothelin is involved in the occurrence and development of essential hypertension, and can increase the cerebral vascular damage.
出处 《中国现代医生》 2010年第13期1-2,5,共3页 China Modern Doctor
基金 2008年度珠海市科技局立项课题 项目编号:PC20081045 项目名称:高血压脑血管阻力与血AngⅡ ET及血压变异性的研究
关键词 高血压 血压变异性 内皮素 Hypertension Blood pressue variability Endothelin
  • 相关文献

参考文献7

  • 1Su DF,Miao CY. Blood pressure variability and organ damage[J]. J Clin Exp Phamacol Physiol,2001,28:709-715.
  • 2Hirsch AT. Vascular disease, hypertension, and prevention : from endothelium to clinical events[J]. J Am Coll Cardiol, 2003,42(2):377-379.
  • 3刘力生 龚兰生.中国高血压防治指南(2005年修订版).中国卒中杂志,2005,1(8):575-582.
  • 4崔伟,郑兴.内皮素及其对心血管疾病的治疗学意义[J].心血管病学进展,2003,24(6):470-473. 被引量:5
  • 5Wedwood S,Black SM. Endotheline-1 decreases endothelial NOS expression and activity through ET receptor mediated seneratlon of hydrosen peroxide[J]. Am J Physiol Lung Cell Mol Physiol, 2005,288 : L480-487.
  • 6Spencer CG, Martin SC, Felmeden DC, et al. Relationship of homocysteine to markers of platelet and endothelial activation in ‘high risk'hypertensiires a substudy of the Anglog Scandinavian Cardiac Outcomes Trial[J]. Int J Cardial, 2007,94( 223 ) : 293-300.
  • 7陈明,胡申江.高血压病血管内皮功能障碍及治疗[J].心血管病学进展,2005,26(3):222-226. 被引量:31

二级参考文献44

  • 1Barton M, Kiowski W. The therapeutic potential of endothelin receptor antagonists in cardiovascular diseMe[ J]. Curt Hypertens Rep,2001,3(4) :322-330.
  • 2Kaur S, Frishman WH, Singh i, el al. Endothelln as a therapeutic target in the treatment of cardiovaseular disease[ J ]. Heart Disease,2001, ( 3 ) : 176-188.
  • 3Ruschitska F,Quaschning T,Noll G,et al. Endothelin 1 type a receptor antagonism prevents vueular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition : role of nitric oxide [ J ]. Circulation, 2001,103(25) :3129-3135.
  • 4Donckier JE, Musart PE,Hodeise D ,et al. Additional hypotensive ef endothelin-1 receptor antagonism in hypertensive dogs under angionism converting enzyme inhibition[J]. Circulation. 1997.96 : 1250-1265.
  • 5Best PJ,Lerman A. F.ndothelin in cardiovascular disease :from atheroscleroeis to heart failure[J]. J Cardiovasc Pharmacol,2000.35 (4 suppl 2) :S61-S63.
  • 6Watanabe T,Suzuki N, Shimamoto N,et al. Contribution of endogenous endothelins to the extension of myocardial infarct size in rats [ J ]. Circ Res, 1991,69 :370-377.
  • 7Giannessi D, Del-Ry S, Vitole R L. The role of endothelins and their receptors in heart failure[J]. Pharmacol Res.2001.43(2) :111-126.
  • 8Fraccarollo D, Bauersachs J, Galuppo P, et al. Effects of combined endothelin Areceptor blockade plus ACE inhibition in rata with symptomatic severe chronic heart failure[J]. J Am Coll Cardiol,2001,37(suppl A) :151A.
  • 9Yorikane R,Sakai S, Miyauchi T,et al. Possible involvement of endothelin-1 in cardiac hypertrophy[J]. Arsneimittelforschung 1994,44:412-415.
  • 10Merkely B, Szabo, Geller L, et al. The selective endothelin-A-receptor antagonist LU135. 252 inhibits the direct arrhythmogenic action of endothelin-1[J]. J Am Coll Cardiol,2000,36( suppl 1 ) :S314-S316.

共引文献51

同被引文献39

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部